|
2. Etiologie
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
|
5. Traitements
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.2 Pharma
|
|
|
Novartis, Colombia face off over cancer drug cost [STAT]
|
|
|
|
|
|
Such
strong-arm tactics may be business as usual in Washington, but they
don’t help burnish Novartis’s reputation. The company is certainly
entitled to chase profits, but it will have to do some damage control
after this mess is cleared up.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.6 ESMO
|
|
|
ESMO 2016 Media Alert: From Disease Treatment to Patient Care [ESMO]
|
|
|
|
|
|
With
USA, Italy, Spain, France and Japan being the top five submitters, the
ESMO 2016 Congress will be a truly international convention at which to
learn about the latest advances in cancer, discuss clinical challenges
and share best practices in order to improve patient treatment and care.
|
|
|
|
|
|
|
5.9.3 EHA
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
Clinton vs. Trump: A race between a policy wonk and a ‘black box’ [STAT]
|
|
|
|
|
|
It’s
not unusual in presidential elections for the two candidates to have
wildly different approaches to health care, or even for the Democratic
nominee to talk about it more than the Republican nominee. What’s
unusual in this race is how vast the imbalance is between Clinton’s
track record — whatever one thinks of it — and Trump’s lack of one.
|
|
|
|
|
|
|
|
6.6 Publications
|
|
|